Antiviral therapy for Epstein-Barr virus-associated diseases

Tzu Chi Medical Journal

Volumn 17, Issue 1, 2005, Pages

  Lin, Jung Chung ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Antiviral therapy; EBV; Latent infection; Nucleoside analogs; Replication

Indexed keywords

2,6 DIAMINO 9 (2 PHOSPHONOMETHOXYETHYL)PURINE; 2,6 DIAMINO 9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)PURINE; 5 (2 BROMOVINYL) 2' DEOXYURIDINE; 5 VINYL 1 BETA DEXTRO ARABINOFURANOSYLURACIL; 9 (2,3 DIHYDROXYPROPYL)ADENINE; 9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; ACICLOVIR; ADEFOVIR; ANTIBIOTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTIVIRUS AGENT; CIDOFOVIR; CLEVUDINE; CYCLOPHOSPHAMIDE; CYTOKINE; ENZYME INHIBITOR; FIACITABINE; FIALURIDINE; GLYCYRRHIZIC ACID; IMMUNOMODULATING AGENT; NUCLEOSIDE DERIVATIVE; RIBOZYME; SMALL INTERFERING RNA; SORIVUDINE; UNCLASSIFIED DRUG; URACIL ARABINOSIDE; VIRAL DNA POLYMERASE INHIBITOR; VIRUS DNA; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; BURKITT LYMPHOMA; CLINICAL FEATURE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; EPSTEIN BARR VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IC 50; INFECTIOUS MONONUCLEOSIS; NASOPHARYNX CANCER; NONHUMAN; REVIEW; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 14244256137     PISSN: 10163190     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Rickinson AB, Kieff E: Epstein-Barr Virus. In: Fields BN, Knipe DM, eds. Fields Virology, 3rd ed., Philadelphia: Lippincott Raven Publishers, 1996, pp 2397-2446.
2. Bonnet M, Guinebretiere JM, Kremmer E, et al: Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst 1999; 18:1376-1381.
3. Fukayama M, Hayashi Y, Iwasaki Y, et al: Epstein-Barr virus-associated gastric carcinoma and Epstein-Barr virus infection of the stomach. Lab Invest 1994; 71:73-81.
4. Fukayama M, Chong JM, Kaizaki Y: Epstein-Barr virus and gastric carcinoma. Gastric Cancer 1998; 1:104-114.
5. Ziegler JL, Drew WL, Miner RC, et al: Outbreak of Burkitt's-like lymphoma in homosexual men. Lancet 1982; 2:631-633.
6. Cooper DA, Pehrson PO, Pedersen C, et al: The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: A double-blind randomized trial. European-Australian Collaborative Group. AIDS 1993; 7:197-207.
7. Pagano JS: Gertrude and Werner Henle lecture on viral oncology. From latency to replication: Recent studies of the Epstein-Barr virus. In: Ablashi DV, Faggioni A, eds. Epstein-Barr Virus and Human Disease, Totowa, New Jersey: Humana Press, 1991, pp 19-32.
8. Raab-Traub N, Flynn K: The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986; 47:883-889.
9. Yates J, Warren N, Reisman D, Sugden B: A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci USA 1984; 81: 3806-3810.
10. Reisman D, Yates J, Sugden B: A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components. Mol Cell Biol 1985; 5:1822-1832.
11. Reisman D, Sugden B: Trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Mol Cell Biol 1986; 6:3838-3846.
12. Rawlins D, Milman G, Hayward SD, Hayward GS: Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell 1985; 42:859-868.
13. Lin JC, Smith MC, Pagano JS: Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus. J Virol 1984; 50:50-55.
14. Hammerschmidt W, Sugden B: Identification and characterization of ori-Lyt, a lytic origin of DNA replication of Epstein-Barr virus. Cell 1988; 55:427-433.
15. Sato H, Takimoto T, Tanaka S, Tanaka J, Raab-Traub N: Concatameric replication of Epstein-Barr virus: Structure of the termini in virus-producer and newly transformed cell lines. J Virol 1990; 64:5295-5300.
16. Zur Hausen H, O'Neill FJ, Freese UK, Hecker E: Persisting oncogenic herpesvirus induced by the tumor promoter TPA. Nature 1978; 272:373-375.
17. Lin JC, Shaw JE, Smith MC, Pagano JS: Effect of 12-0-tetradecanoyl- phorbol-13-acetate on the replication of Epstein-Barr virus. I. Characterization of viral DNA. Virology 1979; 99:183-187.
18. Countryman J, Miller G: Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous DNA. Proc Natl Acad Sci USA 1985; 82:4085-4089.
19. Rooney CM, Rowe DT, Ragot T, Farrell PJ: The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early promoter and induces the virus productive cycle. J Virol 1989; 63:3109-3116.
20. Kenney S, Kamine J, Holley-Guthrie E, Lin JC, Mar EC, Pagano JS: The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters. J Virol 1989; 63:1729-1736.
21. Fixman ED, Hayward GS, Hayward D: Transacting requirements for replication of Epstein-Barr virus ori-Lyt. J Virol 1992; 54:561-568.
22. Lin JC, Sista ND, Besencon F, Kamine J, Pagano JS: Identification and functional characterization of Epstein-Barrvirus DNA polymerase by in vitro transcription-translation of a cloned gene. J Virol 1991; 65:2728-2731.
23. Lin JC, De BK, Mar EC: Functional characterization of partially purified Epstein-Barr virus DNA polymerase expressed in the baculovirus system. Virus Genes 1994; 8:231-241.
24. Tsurumi T, Kobayashi A, Tamai K, Daikoku T, Kurachi R, Nishiyama Y: Functional expression and characterization of the Epstein-Barr virus DNA polymerase catalytic subunit. J Virol 1993; 67:4651-4658.
25. Li JS, Zhou BS, Dutschman GE, Grill SP, Tan RS, Cheng YC: Association of Epstein-Barr virus early antigen diffuse component and virus-specified DNA polymerase activity. J Virol 1987; 61:2947-2949.
26. Tsurumi T, Daikoku T, Kurachi R, Nishiyama Y: Functional interaction between Epstein-Barr virus DNA polymerase catalytic subunit and its accessory subunit in vitro. J Virol 1993; 67:7648-7653.
27. Furnari FB, Adams MD, Pagano JS: Unconventional processing of the 3′ termini of the Epstein-Barr virus DNA polymerase mRNA. Proc Natl Acad Sci USA 1993; 90:378-382.
28. Furnari FB, Adams MD, Pagano JS: Regulation of the Epstein-Barr virus DNA polymerase gene. J virol 1993; 66:2837-2845.
29. Kenney S, Kamine J, Holley-Guthrie E, et al: The Epstein-Barr virus immediate-early gene product, BMLF1, acts in trans by a post-transcriptional mechanism which is reporter gene dependent. J Virol 1989; 63:3870-3877.
30. Hurley EA, Agger S, McNeil JA, et al: When Epstein-Barr virus persistently infects B-cell lines, it frequently integrates. J Virol 1991; 65:1245-1254.
31. Gulley ML, Raphael M, Lutz CT, Ross DW, Raab-Traub N: Epstein-Barr virus integration in human lymphomas and lymphoid cell lines. Cancer 1992; 70:185-191.
32. Pagano JS: Epstein-Barr virus: Therapy of active and latent infection. In: Jeffries DJ, Clercq E De, eds. Antiviral Chemotherapy. Chichester, England: John Wiley & Sons Ltd., 1995, pp 155-195.
33. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ: Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 1977; 74:5716-5720.
34. Miller WH, Miller RL: Phosphorylation of acyclovir diphosphate by cellular enzymes. Biochem Pharmacol 1982; 31:3879-3884.
35. Lin JC, Pagano JS: Cellular transformation by the herpesviruses and antiviral drugs. Pharmacol Ther 1985; 28:135-161.
36. Lin JC, Smith MC, Cheng YC, Pagano JS: Epstein-Barr virus: Inhibition of replication by three new drugs. Science 1983; 221:578-579.
37. Nonoyama M, Pagano JS: Separation of Epstein-Barr virus DNA from large chromosomal DNA in non-virus-producing cells. Nat New Biol 1972; 238:169-171.
38. Lin JC: Strategies for evaluation of antiviral agents against Epstein-Barr virus in culture. In: Kinchington D, Schinazi RF, eds. Methods in Molecular Medicine: Antiviral Chemotherapy Protocols, Totowa, New Jersey: The Humana Press, 1999, pp 139-150.
39. Lo YM, Chan AT, Chan LY, et al: Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res 2000; 60:6878-6881.
40. Pompei R, Flore O, Marccialis MA, Pani A, Loddo B: Glycyrrhic acid inhibits virus growth and inactivates virus particles. Nature 1979; 281:689-690.
41. Baba M, Shigeta S: Antiviral activity of glycyrrhizin against varicella-zoster virus in vitro. Antiviral Res 1987; 7:99-107.
42. Numazaki K, Nagata N, Sato T, Chiba S: Effect of glycyrrhizin, cyclosporin A, and tumor necrosis factor a on infection of U-937 and MRC-5 cells by human cytomegalovirus. J Leukoc Biol 1994; 55:24-28.
43. Crance JM, Leveque F, Biziagos E, van Cuyck-Gandre H, Jouan A, Deloince R: Studies on mechanism of action of glycyrrhizin against hepatitis A virus replication in vitro. Antiviral Res 1994; 23:63-76.
44. Sato H, Goto W, Yamamura J, et al: Therapeutic basis of glycyrrhizin on chronic hepatitis B. Antiviral Res 1996; 30:171-177.
45. Arase Y, Ikeda K, Murashima N, et al: The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997; 79:1494-1500.
46. Ito M, Nakashima H, Baba M, et al: Mechanism of inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus [HIV(HTLV-III/LAV)]. Antiviral Res 1987; 7:127-137.
47. Ito M, Sato A, Hirabayashi K, et al: Mechanism of inhibitory effect of glycyrrhizin on replication of human immunodeficiency virus (HIV). Antiviral Res 1988; 10:289-298.
48. Utsunomiya T, Kobayashi M, Pollard RB, Suzuki F: Glycyrrhizin, an active component of licorice roots, reduces morbidity and mortality of mice infected with lethal doses of influenza virus. Antimicrob Agents Chemother 1997; 41:551-556.
49. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW: Glycyrrhizin, an active component of licorice roots, and replication of SARS-associated coronavirus. Lancet 2003; 361:2045-2046.
50. Finney RS, Somers GF: The antiinflammatory activity of glycyrrhetinic acid and derivatives. J Pharm Pharmacol 1958; 10:613-620.
51. Abe N, Ebina T, Ishida N: Interferon induction by glycyrrhizin and glycyrrhetinic acid in mice. Microbiol Immunol 1982; 26:535-539.
52. Shinada M, Azuma M, Kawai H, et al: Enhancement of interferon-gamma production in glycyrrhizin-treated human peripheral lymphocytes in response to convanavalin A and to surface antigen of hepatitis B virus. Proc Soc Exp Biol Med 1986; 181:205-210.
53. Van Rossum TG, Vulto AG, Hop WC, Brouwer JT, Niesters HG, Schalm SW: Intravenous glycyrrhizin for the treatment of chronic hepatitis C: A double-blind, randomized, placebo-controlled phase I/II trial. J Gastroenterol Hepatol 1999; 14:1093-1099.
54. Tsubota A, Kumada H, Arase Y, et al: Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: A randomized controlled trial in 170 patients. Eur J Gastroenterol Hepatol 1999; 11:1077-1083.
55. Lin JC: Mechanism of action of glycyrrhizic acid in inhibition of Epstein-Barr virus replication in vitro. Antiviral Res 2003; 59:41-47.
56. Lin JC, Smith MC, Pagano JS: Comparative efficacy and selectivity of some nucleoside analogs against Epstein-Barr virus. Antimicrob Agents Chemother 1985; 27:971-973.
57. Lin JC: Antiviral therapy for Epstein-Barr virus: The challenge ahead. Recent Res Development Antimicrob Agents Chemother 1999; 3:191-223.
58. Lin JC, Smith MC, Choi EI, De Clercq E, Verbruggen A, Pagano JS: Effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine on replication of Epstein-Barr virus in human lymphoblastoid cell lines. Antiviral Res 1985; (Suppl 1):121-126.
59. Lin JC, Machida H: Comparison of two bromovinyl nucleoside analogs, 1-β-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil and E-5-(2-bromovinyl)- 2′-deoxyuridine, with acyclovir in inhibition of Epstein-Barr virus replication. Antimicrob Agents Chemother 1988; 32:1068-1072.
60. Lin JC, Reefschlager J, Herrmann G, Pagano JS: Structure-activity relations between (E)-5-(2-bromobinyl) and 5-vinyl-1-β-D- arabinofuranosyluracil (BV-araU, V-araU) in inhibition of Epstein-Barr virus replication. Antiviral Res 1992; 17:43-52.
61. Lin JC, De Clercq E, Pagano JS: Novel acyclic adenosine analogs inhibit Epstein-Barr virus replication. Antimicrob Agents Chemother 1987; 31:1431-1433.
62. Lin JC, De Clercq E, Pagano JS: Inhibitory effects of acyclic nucleoside phosphonate analogs, including (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine, on Epstein-Barr virus replication. Antimicrob Agents Chemother 1991; 35:2440-2443.
63. Gahn TA, Schildkraut CL: The Epstein-Barr virus origin of plasmid replication, oriP, contains both the initiation and termination sites of DNA replication. Cell 1989; 58:527-535.
64. Lin JC, Raab-Traub N, Pagano JS: Disruption of Epstein-Barr virus episomal DNA maintenance by a specific oligodeoxyribonucleotide. Antiviral Res 1990; 70 (Suppl 1):76.
65. Pagano JS, Jimenez G, Sung NS, Raab-Traub N, Lin JC: Epstein-Barr viral latency and cell immortalization as targets for antisense oligomers. Ann NY Acad Sci 1992; 660:107-116.
66. Huang S, Stupack D, Mathias P, Wang Y, Nemerow G: Growth arrest of Epstein-Barr virus immortalized B lymphocytes by adenovirus-delivered ribozymes. Proc Natl Acad Sci USA 1997; 94:8156-8161.
67. Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C: Comparison of antisense oligonucleotides and siRNA in cell culture and in vivo. Biochem Biophys Res Commun 2002; 296:1000-1004.